Loading…
Misoprostol in the prevention of postpartum hemorrhage
OBJECTIVE: To evaluate the data regarding the use of misoprostol in the prevention of postpartum hemorrhage. DATA SOURCES: Pertinent literature was identified through a MEDLINE search (1966–January 2001) and through other secondary literature databases and/or bibliographies of pertinent articles. DA...
Saved in:
Published in: | The Annals of pharmacotherapy 2001-12, Vol.35 (12), p.1648-1652 |
---|---|
Main Authors: | , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c374t-2b2e195b79830e4dbf904a4eccd382e31ae1ae00008cc783d355f97d14f8abd63 |
---|---|
cites | cdi_FETCH-LOGICAL-c374t-2b2e195b79830e4dbf904a4eccd382e31ae1ae00008cc783d355f97d14f8abd63 |
container_end_page | 1652 |
container_issue | 12 |
container_start_page | 1648 |
container_title | The Annals of pharmacotherapy |
container_volume | 35 |
creator | Mategrano, VA Gabay, MP |
description | OBJECTIVE:
To evaluate the data regarding the use of misoprostol in the prevention of postpartum hemorrhage.
DATA SOURCES:
Pertinent literature was identified through a MEDLINE search (1966–January 2001) and through other secondary literature databases and/or bibliographies of pertinent articles.
DATA SYNTHESIS:
New strategies in the prevention of postpartum hemorrhage are being evaluated due to the obstacles surrounding conventional therapies. One therapeutic option is the use of misoprostol. This literature review evaluates the published clinical data involving misoprostol in the prevention of postpartum hemorrhage. Current data suggest that the use of misoprostol for the prevention of postpartum hemorrhage reduces mean estimated blood loss compared with placebo. However, no clinical trials have detected a statistically significant decrease in the incidence of postpartum hemorrhage in misoprostol-treated subjects. There is conflicting evidence regarding the efficacy of misoprostol compared with conventional uterotonics, such as oxytocin or Syntometrine.
CONCLUSIONS:
In situations where conventional oxytocics are not readily available, storage requirements for oxytocics cannot be met, or the equipment for parenteral administration is not obtainable, misoprostol may be an acceptable prophylactic option. |
doi_str_mv | 10.1345/aph.1A100 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72399734</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1345_aph.1A100</sage_id><sourcerecordid>72399734</sourcerecordid><originalsourceid>FETCH-LOGICAL-c374t-2b2e195b79830e4dbf904a4eccd382e31ae1ae00008cc783d355f97d14f8abd63</originalsourceid><addsrcrecordid>eNptkE1LxDAQhoMo7rp68A9ILyoeuuarTXNcFr9gxYueQ5pOt136ZdJa_PdGt7AXYSADeZh550HokuAlYTy6112xJCuC8RGak4jTMKYCH_sexzjENMEzdObcDmMsCZWnaEaIkCxm8RzFr6VrO9u6vq2Csgn6AoLOwhc0fdk2QZsHnf_rtO2HOiigbq0t9BbO0UmuKwcX07tAH48P7-vncPP29LJebULDBO9DmlIgMkqFTBgGnqW5xFxzMCZjCQVGNPjyuXBijEhYxqIolyIjPE90msVsgW72c33EzwFcr-rSGagq3UA7OCUok1Iw7sG7PWj8Lc5Crjpb1tp-K4LVryTlJak_SZ69moYOaQ3ZgZyseOB6ArQzusqtbkzpDhzjWMQkOqRzXonatYNtvIx_N97uwaLcFmNpQblaV5XfT9Q4jixShCoS84T9AH1WiMs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72399734</pqid></control><display><type>article</type><title>Misoprostol in the prevention of postpartum hemorrhage</title><source>SAGE</source><creator>Mategrano, VA ; Gabay, MP</creator><creatorcontrib>Mategrano, VA ; Gabay, MP</creatorcontrib><description>OBJECTIVE:
To evaluate the data regarding the use of misoprostol in the prevention of postpartum hemorrhage.
DATA SOURCES:
Pertinent literature was identified through a MEDLINE search (1966–January 2001) and through other secondary literature databases and/or bibliographies of pertinent articles.
DATA SYNTHESIS:
New strategies in the prevention of postpartum hemorrhage are being evaluated due to the obstacles surrounding conventional therapies. One therapeutic option is the use of misoprostol. This literature review evaluates the published clinical data involving misoprostol in the prevention of postpartum hemorrhage. Current data suggest that the use of misoprostol for the prevention of postpartum hemorrhage reduces mean estimated blood loss compared with placebo. However, no clinical trials have detected a statistically significant decrease in the incidence of postpartum hemorrhage in misoprostol-treated subjects. There is conflicting evidence regarding the efficacy of misoprostol compared with conventional uterotonics, such as oxytocin or Syntometrine.
CONCLUSIONS:
In situations where conventional oxytocics are not readily available, storage requirements for oxytocics cannot be met, or the equipment for parenteral administration is not obtainable, misoprostol may be an acceptable prophylactic option.</description><identifier>ISSN: 1060-0280</identifier><identifier>EISSN: 1542-6270</identifier><identifier>DOI: 10.1345/aph.1A100</identifier><identifier>PMID: 11793636</identifier><identifier>CODEN: APHRER</identifier><language>eng</language><publisher>Cincinnati, OH: Harvey Whitney Books</publisher><subject>Biological and medical sciences ; Clinical Trials as Topic ; Female ; Genital system. Reproduction ; Humans ; Medical sciences ; Misoprostol - therapeutic use ; Oxytocics - therapeutic use ; Pharmacology. Drug treatments ; Postpartum Hemorrhage - etiology ; Postpartum Hemorrhage - prevention & control ; Pregnancy</subject><ispartof>The Annals of pharmacotherapy, 2001-12, Vol.35 (12), p.1648-1652</ispartof><rights>2001 SAGE Publications</rights><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c374t-2b2e195b79830e4dbf904a4eccd382e31ae1ae00008cc783d355f97d14f8abd63</citedby><cites>FETCH-LOGICAL-c374t-2b2e195b79830e4dbf904a4eccd382e31ae1ae00008cc783d355f97d14f8abd63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925,79364</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13407615$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11793636$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mategrano, VA</creatorcontrib><creatorcontrib>Gabay, MP</creatorcontrib><title>Misoprostol in the prevention of postpartum hemorrhage</title><title>The Annals of pharmacotherapy</title><addtitle>Ann Pharmacother</addtitle><description>OBJECTIVE:
To evaluate the data regarding the use of misoprostol in the prevention of postpartum hemorrhage.
DATA SOURCES:
Pertinent literature was identified through a MEDLINE search (1966–January 2001) and through other secondary literature databases and/or bibliographies of pertinent articles.
DATA SYNTHESIS:
New strategies in the prevention of postpartum hemorrhage are being evaluated due to the obstacles surrounding conventional therapies. One therapeutic option is the use of misoprostol. This literature review evaluates the published clinical data involving misoprostol in the prevention of postpartum hemorrhage. Current data suggest that the use of misoprostol for the prevention of postpartum hemorrhage reduces mean estimated blood loss compared with placebo. However, no clinical trials have detected a statistically significant decrease in the incidence of postpartum hemorrhage in misoprostol-treated subjects. There is conflicting evidence regarding the efficacy of misoprostol compared with conventional uterotonics, such as oxytocin or Syntometrine.
CONCLUSIONS:
In situations where conventional oxytocics are not readily available, storage requirements for oxytocics cannot be met, or the equipment for parenteral administration is not obtainable, misoprostol may be an acceptable prophylactic option.</description><subject>Biological and medical sciences</subject><subject>Clinical Trials as Topic</subject><subject>Female</subject><subject>Genital system. Reproduction</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Misoprostol - therapeutic use</subject><subject>Oxytocics - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Postpartum Hemorrhage - etiology</subject><subject>Postpartum Hemorrhage - prevention & control</subject><subject>Pregnancy</subject><issn>1060-0280</issn><issn>1542-6270</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><recordid>eNptkE1LxDAQhoMo7rp68A9ILyoeuuarTXNcFr9gxYueQ5pOt136ZdJa_PdGt7AXYSADeZh550HokuAlYTy6112xJCuC8RGak4jTMKYCH_sexzjENMEzdObcDmMsCZWnaEaIkCxm8RzFr6VrO9u6vq2Csgn6AoLOwhc0fdk2QZsHnf_rtO2HOiigbq0t9BbO0UmuKwcX07tAH48P7-vncPP29LJebULDBO9DmlIgMkqFTBgGnqW5xFxzMCZjCQVGNPjyuXBijEhYxqIolyIjPE90msVsgW72c33EzwFcr-rSGagq3UA7OCUok1Iw7sG7PWj8Lc5Crjpb1tp-K4LVryTlJak_SZ69moYOaQ3ZgZyseOB6ArQzusqtbkzpDhzjWMQkOqRzXonatYNtvIx_N97uwaLcFmNpQblaV5XfT9Q4jixShCoS84T9AH1WiMs</recordid><startdate>20011201</startdate><enddate>20011201</enddate><creator>Mategrano, VA</creator><creator>Gabay, MP</creator><general>Harvey Whitney Books</general><general>SAGE Publications</general><general>Whitney</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20011201</creationdate><title>Misoprostol in the prevention of postpartum hemorrhage</title><author>Mategrano, VA ; Gabay, MP</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c374t-2b2e195b79830e4dbf904a4eccd382e31ae1ae00008cc783d355f97d14f8abd63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Biological and medical sciences</topic><topic>Clinical Trials as Topic</topic><topic>Female</topic><topic>Genital system. Reproduction</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Misoprostol - therapeutic use</topic><topic>Oxytocics - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Postpartum Hemorrhage - etiology</topic><topic>Postpartum Hemorrhage - prevention & control</topic><topic>Pregnancy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mategrano, VA</creatorcontrib><creatorcontrib>Gabay, MP</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Annals of pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mategrano, VA</au><au>Gabay, MP</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Misoprostol in the prevention of postpartum hemorrhage</atitle><jtitle>The Annals of pharmacotherapy</jtitle><addtitle>Ann Pharmacother</addtitle><date>2001-12-01</date><risdate>2001</risdate><volume>35</volume><issue>12</issue><spage>1648</spage><epage>1652</epage><pages>1648-1652</pages><issn>1060-0280</issn><eissn>1542-6270</eissn><coden>APHRER</coden><abstract>OBJECTIVE:
To evaluate the data regarding the use of misoprostol in the prevention of postpartum hemorrhage.
DATA SOURCES:
Pertinent literature was identified through a MEDLINE search (1966–January 2001) and through other secondary literature databases and/or bibliographies of pertinent articles.
DATA SYNTHESIS:
New strategies in the prevention of postpartum hemorrhage are being evaluated due to the obstacles surrounding conventional therapies. One therapeutic option is the use of misoprostol. This literature review evaluates the published clinical data involving misoprostol in the prevention of postpartum hemorrhage. Current data suggest that the use of misoprostol for the prevention of postpartum hemorrhage reduces mean estimated blood loss compared with placebo. However, no clinical trials have detected a statistically significant decrease in the incidence of postpartum hemorrhage in misoprostol-treated subjects. There is conflicting evidence regarding the efficacy of misoprostol compared with conventional uterotonics, such as oxytocin or Syntometrine.
CONCLUSIONS:
In situations where conventional oxytocics are not readily available, storage requirements for oxytocics cannot be met, or the equipment for parenteral administration is not obtainable, misoprostol may be an acceptable prophylactic option.</abstract><cop>Cincinnati, OH</cop><pub>Harvey Whitney Books</pub><pmid>11793636</pmid><doi>10.1345/aph.1A100</doi><tpages>5</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1060-0280 |
ispartof | The Annals of pharmacotherapy, 2001-12, Vol.35 (12), p.1648-1652 |
issn | 1060-0280 1542-6270 |
language | eng |
recordid | cdi_proquest_miscellaneous_72399734 |
source | SAGE |
subjects | Biological and medical sciences Clinical Trials as Topic Female Genital system. Reproduction Humans Medical sciences Misoprostol - therapeutic use Oxytocics - therapeutic use Pharmacology. Drug treatments Postpartum Hemorrhage - etiology Postpartum Hemorrhage - prevention & control Pregnancy |
title | Misoprostol in the prevention of postpartum hemorrhage |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T09%3A56%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Misoprostol%20in%20the%20prevention%20of%20postpartum%20hemorrhage&rft.jtitle=The%20Annals%20of%20pharmacotherapy&rft.au=Mategrano,%20VA&rft.date=2001-12-01&rft.volume=35&rft.issue=12&rft.spage=1648&rft.epage=1652&rft.pages=1648-1652&rft.issn=1060-0280&rft.eissn=1542-6270&rft.coden=APHRER&rft_id=info:doi/10.1345/aph.1A100&rft_dat=%3Cproquest_cross%3E72399734%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c374t-2b2e195b79830e4dbf904a4eccd382e31ae1ae00008cc783d355f97d14f8abd63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=72399734&rft_id=info:pmid/11793636&rft_sage_id=10.1345_aph.1A100&rfr_iscdi=true |